Evaluation of eicosapentaenoic acid (EPA) for preventing the progression of coronary atherosclerosis and revascularization in patients with dyslipidemia who underwent percutaneous coronary intervention (PCI)
Not Applicable
Recruiting
- Conditions
- Coronary artery disease with dyslipidemia
- Registration Number
- JPRN-UMIN000003947
- Lead Sponsor
- Kurashiki central Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients who have hypersensitivity to EPA 2) Patients who had cerebral accident in the past 6 months 3) Pregnant women and women suspected of being pregnant 4) Patients with gastrointestinal ulcer in active phase 5) Patients with bleeding 6) Patients who have very poor choleresis or severe liver dysfunction 7) Patients who are ineligible for this study 8) Patients with severe renal dysfunction or undergoing dialysis
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method In non-PCI lesions with >= 50% stenosis according to the AHA classification, 1) change in MLD during the follow-up period 2) coronary revascularization
- Secondary Outcome Measures
Name Time Method MACCE: death, nonfatal myocardial infarction, cerebral accident, unstable angina requiring hospitalization